REG - Deepverge PLC - Compact Microtox® PD launch scheduled for Q1 2022

DeepvergeAnnouncement

10/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211210:nRSJ2004Va&default-theme=true

RNS Number : 2004V  Deepverge PLC  10 December 2021

10 December 2021

 

DeepVerge PLC

 

("DeepVerge" or "Company")

 

Launch of compact Microtox(®) PD i  (#_edn1)  surveillance units in Q1 2022

 

Detects SARS-CoV-2 and a range of pathogens at local, regional and national
levels

 

New service bridges gap between real-time detection and variant identification
where people gather

 

Modern Water, a division of DeepVerge (AIM: DVRG) announces the completion of
development of the 3(rd) generation compact Microtox(®) PD COVID detection
system, which is now scheduled for launch in the first quarter of 2022.  The
upgraded Microtox(®) PD system significantly expands pandemic surveillance
capabilities to towns, villages, hospitals, hotels, ports, locations where
large groups of people gather, extending the reach of real-time national
pandemic response to local community level.

 

Modern Water Mobile Services ("MWMS")

 

MWMS is positioned as a critical new component in the armoury of national and
provincial government response protocol. It allows utilities to extend their
reach into smaller sites for more granular 'last mile' surveillance, enabling
local authorities and private companies to protect citizens and customers by
monitoring for COVID and a range of additional pathogens, including forever
chemicals.

 

Benefits include:

 

1.       Real-time detection of the virus in the community at source,

2.       Zero transport costs of non-virus confirmed samples, and

3.       Variant testing only on confirmed virus at the laboratory.

 

Gerry Brandon, CEO of DeepVerge plc, commented:

 

"Size, cost, reach and route to market have been heavily thought through with
our new 3(rd) generation designs. The units are now smaller - allowing them to
be installed for smaller populations; mobile - allowing them to be taken to
where populations gather; mass producible - allowing more affordability for
customers; and just as importantly, available for new partner opportunities.
We have also built into our business model the capability for these units to
be manufactured and franchised to companies in the developing world, to be
sold at locally affordable prices.

 

"Over the last 18 months, we recognised the potential of our tech for mass
surveillance for the benefit of public health - from monitoring large
populations down to individual monitoring. It is our vision for Microtox(®)
PD to become a standard part of home or office utility and this latest
generation model is a giant leap towards that vision being reality."

 

Microtox(®) BT

 

The Microtox(®) BT equipment was also re-designed to deliver a portable,
mobile testing unit to process breath tests at point of care. The established
test protocols have been carried out at Labskin from test subjects provided by
the Royal College of Surgeons in Ireland for the early prototype and secured
positive results. Regulatory approvals for human diagnostic equipment is
evaluated on test equipment that will be used on humans. Therefore, roll out
of the breath test is subject to meeting the satisfactory requirements of EU
Regulatory approvals which will be carried out on the latest version of the
Microtox(®) BT units. Further information on this will be provided in H1
2022.

 

 

Enquiries:

 

 DeepVerge plc                                   Gerry Brandon, CEO       +44 (0) 734 0055 648
 SPARK Advisory Partners Limited                 Neil Baldwin             +44 (0) 113 370 8974

 (Nominated Adviser)
 Turner Pope Investments (TPI) Limited (Broker)  Andy Thacker/James Pope  +44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER
THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF
ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com (http://www.deepverge.com) )

 

DeepVerge is an environmental and life science group of companies that
develops and applies AI and IoT technology to analytical instruments for the
analysis and identification of bacteria, virus and toxins. Utilising
artificial intelligent data analytics to scientifically prove the impact of
skincare product claims on skin microbiome for most of the top 20 global
cosmetic company clients and remotely detect and identify in real-time,
dangerous pathogens in wastewater treatment plants, drinking water, rivers,
lakes and reservoirs.

 

 i  (#_ednref1) Microtox(®) PD has been designed to be retrofitted into
existing Modern Water equipment to detect and identify a range of infectious
viruses and bacteria including SARS-CoV-2, E.coli, Legionella and
Cryptosporidium, on a single chip, using AI, in real-time. New compact version
is 100% portable.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDKCBNFBDDPBK